Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Net Income towards Common Stockholders (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Net Income towards Common Stockholders for 8 consecutive years, with -$23.1 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 232.69% to -$23.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$102.9 million through Dec 2025, down 376.77% year-over-year, with the annual reading at -$62.4 million for FY2025, 17.17% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$23.1 million at Outlook Therapeutics, down from -$13.3 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $17.4 million in Q4 2024, with the low at -$46.4 million in Q1 2025.